MG
BOLD

Michael Gelband’s Boundless Bio BOLD Stock Holding History

Michael Gelband’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,328
Closed -$60K – 2156
2024
Q3 		$60K Sell
17,328
-198,239
-92% -$718K ﹤0.01% 1534
2024
Q2 		$834K Buy
215,567
+115,567
+116% +$1.1M 0.01% 1084
2024
Q1 		$1.43M Buy
+100,000
New +$1.43M 0.01% 830

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Michael Gelband's BOLD Position: Q4 2024 in Review

Michael Gelband sold out of Boundless Bio (BOLD) in Q4 2024, closing a stake of 17,328 shares — an estimated $60K sold.

Michael Gelband first reported a position in BOLD in Q1 2024 and held it in 3 quarters. The position peaked at $1.43M in Q1 2024. 55 funds tracked by Wall St. Rank hold BOLD as of Q4 2024.

  • Michael Gelband reported no remaining Boundless Bio position as of Q4 2024 after selling out during the quarter.
  • Michael Gelband sold 17,328 Boundless Bio shares in Q4 2024, an estimated $60K.
  • Michael Gelband first reported a position in Boundless Bio in Q1 2024 and held it in 3 quarters.
  • Michael Gelband's Boundless Bio position peaked at $1.43M in Q1 2024.
  • 55 funds tracked by Wall St. Rank held Boundless Bio as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.